Videos & Webinars

Webinar: Going beyond EGFR – Evaluating Technologies for Molecular Genetic Testing in NSCLC

24 July 2020

What’s the sensitivity required for optimal molecular testing in NSCLC? Dr. Erwan Pencreach presents the results from a retrospective technical analysis, after a year of routine NSCLC molecular testing with the MassARRAY System, from a biological/clinical and economical point of view.

Topics Include:
  • Understand the role of driver mutations and actionable targets, like T790M, L858R and exon 19 deletions in EGFR.
  • Supplement clinical analyses of routine NSCLC molecular testing with economic considerations.
  • Evaluate the MassARRAY technology for melanoma, lung, breast and colon cancers in comparison with NGS.

Presented by:
Erwan Pencreach, PharmD, PhD
Department of Molecular Oncology, Strasbourg University Hospital, France

Recorded on July 28, 2020